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Abstract
Human respiratory syncytial virus (HRSV) is the major cause of lower respiratory tract infections in children under 5 years of
age and the elderly, causing annual disease outbreaks during the fall and winter. Multiple lineages of the HRSVA and HRSVB
serotypes co-circulate within a single outbreak and display a strongly temporal pattern of genetic variation, with a
replacement of dominant genotypes occurring during consecutive years. In the present study we utilized phylogenetic
methods to detect and map sites subject to adaptive evolution in the G protein of HRSVA and HRSVB. A total of 29 and 23
amino acid sites were found to be putatively positively selected in HRSVA and HRSVB, respectively. Several of these sites
defined genotypes and lineages within genotypes in both groups, and correlated well with epitopes previously described in
group A. Remarkably, 18 of these positively selected tended to revert in time to a previous codon state, producing a ‘‘flip-
flop’’ phylogenetic pattern. Such frequent evolutionary reversals in HRSV are indicative of a combination of frequent
positive selection, reflecting the changing immune status of the human population, and a limited repertoire of functionally
viable amino acids at specific amino acid sites.
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Introduction
Human respiratory syncytial virus (HRSV) is a leading cause of
severe acute respiratory infection in childhood worldwide [1] and an
important agent of acute respiratory infection in the elderly and
immunocompromised [2,3]. Initial studies with monoclonal antibod-
ies to the HRSV F and G proteins divided the virus into two major
groups (A and B) [4,5]. Sequencing studies based on several HRSV
genes have supported this major subdivision and lead to an additional
genotypic classification, mainly based on the G protein gene, for
epidemiological studies of HRSV. The genotypes of HRSVA and B
show complex fluctuating dynamics, since they may co-circulate
during a given season, with one or two dominant genotypes that are
then replaced in consecutive years [6,7,8,9,10,11].
The G protein is a target for neutralizing antibodies, interacts
with host cell receptors and is highly variable [12,13,14,15]. Most
changes in the G protein are localized at an ectodomain
containing two hyper-variable segments, separated by a highly
conserved region between amino acids 164 and 176, assumed to
represent a receptor-binding site [15]. Experimental data show
that the G protein is not required for virus infection in vitro under
appropriate conditions, but is necessary for efficient infection in
mice and humans [16]. It has been argued that the antigenic
variability of HRSV strains is one of the key features contributing
to the ability of the virus to re-infect people and cause large-scale
yearly outbreaks [17]. Moreover, several studies have shown that
the C-terminal hyper-variable region of the surface G glycoprotein
is immunogenic and contains multiple epitopes that are recognized
by both murine monoclonal antibodies and human convalescent
sera [18]. In addition, the deduced amino acid sequences of the G
protein are highly divergent, with a sequence identity of
approximately 53% between HRSVA and B, and 20% divergence
within the same antigenic group [14,19]. Despite this diversity, the
nature of the selection pressures acting on the G protein have not
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that are of sufficient size to reveal the intricate nature of adaptive
evolution and with restricted spatial and temporal sampling. This
information is of particular importance since the ectodomain of
the G-protein is also a target site in vaccines that have so far met
with little success. To addresses these key issues we undertook the
largest analysis of HRSV sequences undertaken to date,
comprising both HRSVA and HRSVB, and utilizing detailed
temporal information.
Methods
Respiratory samples
A total of 3,496 respiratory samples were used in this study.
Nasopharyngeal aspirates and nasal swabs from 2,256 infants and
young children (1 week to 5 years of age) hospitalized with acute
respiratory lower infection (ARI) at University of Sa ˜o Paulo
Hospital, Sa ˜o Paulo, Brazil were used. Samples were collected
over 11 consecutive HRSV seasons (1995–2005). In addition,
1,240 respiratory samples from children with ARI were collected
in 2004 and 2005 in different cities in Sa ˜o Paulo State and enrolled
in the present study as part of the Viral Genetic Diversity Network
(VGDN) (http://www.lemb.icb.usp.br/LEMB/index.php?p=11).
Informed consent was obtained from parents or guardians of
children enrolled in the study in the different cities according to a
protocol approved by their respective Institutional Review Boards.
HRSV screening
Specimens were collected in buffered saline and transported on
ice to the laboratory for processing within 4 hours. A commercial
immunofluorescence assay was used per manufacturer’s instruc-
tions (Chemicon Light Diagnostics, Millipore Corp, Inc., Teme-
cula, CA.), as previously described [20]. Clinical samples were
amplified by RT-PCR as described bellow.
RNA extraction and reverse transcription
Total RNA was extracted using guanidinium isothiocyanate
phenol (Trizol LS, InvitrogenH, Carlsbad, CA) according to the
manufacturer’s instructions. Extracted RNA was annealed with
50 pmol random hexanucleotide primer (InvitrogenH)a t2 5 uC for
25 minutes, followed by reverse transcription with 200 U
SuperScript
TM (InvitrogenH)a t4 2 uC for 1 hour.
PCR and nucleotide sequencing
Partial HRSV G gene amplification was performed by a semi-
nested PCR procedure. cDNA was amplified with reverse primer
FV -59GTTATGACACTGGTATACCAACC 39 (based on
sequences complementary to nucleotides 186 to 163 of the F
protein gene messenger RNA strain CH18537 [21] – and the
forward primer GAB - 59YCAYTTTGAAGTGTTCAACTT
39(G gene, 504–524 nt). A semi-nested PCR was then performed
with primers F1AB -59CAACTCCATTGTTATTTGCC39 (F
gene, 3–22 nt) and GAB [8,9]. PCR assay was carried out in a
reaction mixture containing 2,5 mL of cDNA, 20 mM Tris-HCl,
50 mM KCl, 1,5 mM MgCl2, 0,2 mM dNTPs, 10 pmol of each
primer, 1,25 U of Taq DNA Polimerase (Taq-Gold, Applied
Biosystems Inc) in a final volume of 25 mL. Amplification was
performed in a GeneAmp PCR System 9700 thermocycler
(Applied Biosystems Inc.) with the following parameters: 94uC
for 5 minutes, followed by 35 cycles of 1 min at 94uC, 1 min at
55uC and 1 min at 72uC, and finally 7 min of extension at 72uC.
The semi nested PCR was carried under the same conditions, with
10 pmol of each primer on a final volume of 25 mL. Both cDNA
synthesis and PCR followed strict procedures to prevent
contamination, including redundant negative controls and segre-
gated environments for pre- and post-amplification procedures.
Amplified products of the G gene showing the expected size by gel
electrophoresis, were purified with a commercial kit (Concert Gel
Extraction Systems, InvitrogenH), according to the manufacturer’s
instructions, followed by cycle-sequencing on a GeneAmp PCR
System 9700 thermocycler (Applied Biosystems Inc). Sequence
reactions were subjected to electrophoretic separation for primary
data collection in ABI PRISM 3100 and 377 DNA sequencers
(Applied Biosystems Inc.), using a fluorescent dye terminator kit
(Applied Biosystems Inc.). Both strands were sequenced at least
twice.
Sequence editing and alignments
Sequences were assembled with the Sequence Navigator
program version 1.0 (Applied Biosystems Inc., EUA) resulting in
contigs of 270 nucleotides on average, corresponding to HRSV G
gene nucleotide 649–918 (group A, prototype strain A2) and 652–
921 (group B, prototype strain CH18537). Individual sequences
were aligned to HRSV G references sampled globally [8,9,10,11,
19,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37] with the Se-
Al - Sequence Alignment Editor [38], resulting in data sets with an
average length of 270 nucleotides.
Phylogenetic analyses
Because the strains A2 and Long (A group) and CH18537 and
Sw8/60 (B group) were both the most divergent and considered
prototype strains, they were included in the analysis as outgroup
sequences for the phylogenetic analysis. The best–fit model of
nucleotide substitution (GTR+C+I), and values for the shape
parameter (a) for the distribution of among-site rate-heterogeneity
distribution (C) were selected by hierarchical likelihood ratio
testing using Modeltest Version 3.06 [39]. Using these models,
maximum likelihood (ML) phylogenetic trees were inferred by
heuristic searches using PAUP under sequentially the TBR (Tree
Bisection-Reconnection), SPR (Subtree Pruning Regrafting) and
NNI (Nearest Neighbor Interchange) perturbation procedures
[40], using as BioNJ tree as a starting phylogeny. Levels of
phylogenetic support for individual nodes were obtained by
Author Summary
As part of the Viral Genetic Diversity Network (VGDN), we
sequenced the second variable region (G2) of the G
protein of human respiratory syncytial virus (HRSV) A and B
from 568 patients sampled during 11 consecutive HRSV
seasons (1995–2005) in the state of Sa ˜o Paulo, Brazil. A
total of 933 HRSVA and 673 HRSB time-stamped sequenc-
es, including those sampled here and globally, was used
for phylogenetic inference and the analysis of selection
pressures. We identified 18 positively selected sites in both
HRSVA (9 sites) and HRSVB (9 sites) that tended to revert in
time to their previous codon state (i.e. exhibited a ‘‘flip-
flop’’ pattern). We argue that these common evolutionary
reversals are indicative of frequent positive selection,
reflecting the changing immune status of the human
population, coupled with a limited repertoire of functional
viable amino acids at specific sites. This information is of
particular importance since the ectodomain of the G
protein is also a target site in vaccines that have so far
proven unsuccessful and because it constitutes a signifi-
cant step towards describing and understanding the
immune-escape repertoire of this major human pathogen.
HRSV Evolutionary Reversals
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collected near the likelihood maxima during both the SPR and
NNI branch-swapping procedures. Consensus values above 99%
were used to check for genotype monophyly. Moreover, since
samples had dates of sampling ranging a 30 year period, we also
generated maximum clade credibility (MCC) trees for HRSVA
and HRVB data using the Bayesian inference (BI) method in
BEAST v. 1.4.7 [41]. We used the best fit model (GTR+C4+I)
assuming an uncorrelated lognormal-distributed relaxed clock
with rates of change estimated from the data and using a Bayesian
skyline demographic model as a coalescent prior. To obtain
effective sampling sizes (ESS) above 100, MCC trees for HRSVA
and HRSVB were obtained by pooling five independent Markov-
chain Monte Carlo runs, each of which sampled from 10 million
chains after a pre-burning period of 30 million chains.
Analysis of selection pressures
To detect sites in the G protein that might be subject to positive
selection we used the Bayesian methods implemented in the
HyPhy program [42]. We employed the default
‘MG94xHKY85x3_4x2Rates with Rate heterogeneity, with 4
rate categories per parameter’ model. This estimates multiple
parameters that are free to vary over sites both dN and dS to have
distinct rates at a given site and to be sampled independently from
two separate distributions. For the MG94xHKY85x3_4x2Rates
model we used a Bayes factors .20 means that positive selection
explains the data approximately 20 times better than the
alternative model [42]. For comparison, we also used the less
computationally intensive Single Likelihood Ancestral Counting
(SLAC) and Fixed-Effects Likelihood (FEL) methods using the best
fit nucleotide model estimated with HyPhy for each data set. With
SLAC and FEL, all positively selected sites were estimated at the
95% confidence interval. We did not use the random effects
likelihood method (REL) because of major computational
constraints [42,43,44].
In addition, we obtained the most parsimonious reconstructions
(MPR) of the positively selected sites along both HRSVA and
HRSVB G protein trees using both the ‘accelerated transforma-
tion’ (ACCTRAN) method that maps character changes near the
root of the tree, and the ‘delayed transformation’ (DELTRAN)
method that maps character changes near the tips of the tree
implemented in MacClade v. 4.07 [45]. Because all sequences had
dates of sampling, allowing us to recover temporal patterns of
amino acid replacement, we adjusted the tips of the phylogenies in
time (i.e., tip-dated trees) with BEAST v.1.4.7 (http://beast.bio.ed.
ac.uk/).
Nucleotide sequence accession numbers
The nucleotide sequences from the Brazilian isolates were
deposited in the GenBank database under accession numbers
EU582054 to EU582483, EU635778 to EU635865, EU259652 to
EU259673, EU259675, EU259676, EU259678 to EU259690,
EU259693 to EU259696 to EU259704, EU 625735, EU241632
to EU241634 and AY654589.
Results
HRSV sequencing and genotyping
We obtained nucleotide sequences of the second region (G2) of
the HRSV G protein gene from (i) 432 random samples collected
over 11 seasons (i.e., from 1995 to 2005) from the city of Sa ˜o Paulo,
Brazil and (ii) 136 sequences from samples collected by VGDN
program from 2004 to 2005 from metropolitan area of the city of
Sa ˜o Paulo and from the city of Ribeira ˜o Preto, also in Sa ˜o Paulo
state. Of a total of 568 sequences, 359 (63.2%) represented group
A and 209 (36.8%) group B.
The Brazilian isolates of HSRVA had a deduced G protein of
298 or 297 amino acids, which was confirmed by complete G
protein sequences obtained from several representative samples
used in this study (data not shown). Interestingly, three isolates
(Br89_2000, Br86_2000 and Br 206_2004) had a premature stop
codon at amino acid position 288, which has been observed
previously [46,47] and four Brazilian GA5 strains from 2000 had a
deletion of three bases, causing the loss of a serine residue at
position 270. All the Brazilian isolates of HSRVB had an inferred
G protein of 295 amino acids, except three isolates from 2000
season that had 299 amino acids due to a mutation in the first
nucleotide of the stop codon of G gene, and two strains from 1999
season that had a Threonine codon insertion at position 233,
leading to a G protein with 296 amino acids. Some strains isolated
during 2001, 2003 and 2004 have an exact duplication of 60
nucleotides starting after residue 791 (accounting for a 20 aa
duplication by insertion and resulting in a predicted protein of 312
to 319 aa). In 2005 this new genotype – denoted ‘GB3 with
insertion’ (see below) – became the predominant. The alignment
of partial amino acid sequences including the duplicated G
segment showed some amino acid substitutions in the duplicate
segment and in the 60 nucleotides immediately upstream. A total
of 933 HRSVA sequences and 673 HRSVB sequences, including
original and data compiled from GenBank, were used for further
evolutionary analysis (see Table S1 in supplementary material).
HRSV genotypes
Both the ML and MCC trees divided HRSVA into seven
monophyletic clusters with bootstrap or posterior probability
support above 99%; these were previously described as genotypes
GA1, GA2, GA3, GA4, GA6, GA5, GA7 and SAA1 [8,9,34]. The
MCC tree (Fig. 1) showed that genotypes GA2, GA3, GA4, GA6
and GA7 had a common ancestor not shared by GA5 and GA1.
GA2 strains fell into two distinct branches. One included the oldest
strains isolated from 1995 to 2000 in several regions globally (i.e.,
Brazil, South America, Belgian, United States and Africa). The
other branch grouped the most recently isolated strains (2000 to
2004) that also exhibited a very widespread distribution (i.e.,
Belgian, Brazil, China and Africa). Brazilian strains in this second
branch were characterized by five amino acid substitutions:
Leu215Pro, Arg244Lis, His266Tyr, Asp297Lys and the stop
codon at 298 reverting to Trp (Stop298Trp). These changes were
fixed in almost all 2003 to 2005 GA2 strains.
The MCC tree for HRSVB (Fig. 2) contained 8 clusters that
were previously described as genotypes JA1, GB1, GB2, GB3,
GB4, SAB1, SAB2, SAB3 and GB3 with insertion [8,9,33,34].
These same groupings were observed in the ML tree. GB3 was a
paraphyletic genotype and included both SAB3 and the GB3 with
the 60 nucleotide insertion.
Selective Pressures in HRSV
In total, we found 29 sites to be subject to elevated rates of non-
synonymous substitution (dN) in HRSVA, nine of which were
detected to be under positive selection by the three methods we
used and strongly suggesting that they are not false positives
(Table 1). By using the Long 1956 prototype strain as an outgroup
sequence, the most parsimonious reconstruction of the positively
selected amino acid changes along the HRSVA tip-dated tree
revealed that 22 mapped to the basal node (Fig. 1). That these 22
putatively positively selected sites included the replacement
substitutions that defined the different genotypes and lineages
within genotypes confirmed that they have reached a high
HRSV Evolutionary Reversals
PLoS Pathogens | www.plospathogens.org 3 January 2009 | Volume 5 | Issue 1 | e1000254Figure 1. The most parsimonious reconstructions of positively selected sites on the HRSVA phylogeny rooted with the Long and A2
and GA1 strains (not shown for clarity) are depicted. Basal positively selected sites of HRSVA are indicated near the root of the tree. MPRs
along the tree supporting the main splits are also indicated near the nodes at the base of each genotype. Lineages that did not experience
evolutionary reversals were collapsed for the sake of clarity. For both A) and B) sites experiencing evolutionary mutations (Table 1) are indicated by
the symbols: . for the ‘forward’ (Fr) mutation and , for the ‘backward’ mutation (Br). The Fr I is indicated by blue quadrilateral ., and the Br I by
blue quadrilateral ,. The Fr II is indicated by pink quadrilateral . and the Br II by pink quadrilateral ,. The Fr III is indicated by blue circle . and the
Br III by blue circle ,. The Fr IV is indicated by green circle . and the Br IV by green circle ,. The Fr V is indicated by violet triangle . and the Br V by
violet triangle ,. The Fr VI is indicated by violet circle . and the Br VI by violet circle ,. The Fr VII is indicated by orange quadrilateral . and the Br VII
by orange quadrilateral ,. The Fr VII is indicated by green triangle . and the Br VIII by green triangle ,. The Fr IX is indicated by black triangle . and
the Br by black triangle ,.
doi:10.1371/journal.ppat.1000254.g001
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PLoS Pathogens | www.plospathogens.org 4 January 2009 | Volume 5 | Issue 1 | e1000254Figure 2. The most parsimonious reconstructions of positively selected sites on the HRSVA phylogeny rooted with the CH18537
and SW860 (not shown for clarity) are shown. Basal positively selected sites of HRSVB are indicated near the root of the tree. MPRs along the
tree supporting the main splits are also indicated near the nodes at the base of each genotype. Lineages did not experience evolutionary reversals
were collapsed for the sake of clarity. For both A) and B) sites experiencing evolutionary mutations (Table 1) are indicated by the symbols: pink
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selected sites rather than false-positives. Site 215 had a Leucine
(Leu) in all genotypes except in the non-circulating genotype GA1,
that had a Proline (Pro), and the non-circulating Long 1956
prototype strain, that possessed a Histidine (His). Interestingly,
most GA2 strains isolated after 2000 reverted to Pro at this site,
and most GA5 strains isolate since 2001 changed to Isoleucine
(Ile). Moreover, GA1 was basal to all other HRSVA genotypes and
since it had no reversals on positive selected sites it was excluded
from Fig. 1 for the sake of clarity (Fig. 1). The changes Phe265Leu,
Leu274Pro, Ser280Tyr, Pro286Leu, Ser290Pro and Pro293Ser
mapped to the split of two distinct branches; (i) one containing the
older samples including prototypes (A2 and Long) and non-
circulating genotype GA1 and, (ii) another containing the
remaining genotypes (GA5, GA2, GA3, GA4, GA6 and GA7)
(Fig. 1). Val225Ala, Pro256Leu, Thr238Leu and Leu274Thr
changes defined the GA5 genotype (Fig. 1). Moreover, positively
selected changes Pro289Ser, Pro226Leu, Ser269Thr and Pro290
Leu defined GA2 genotype, while Pro226Leu defined genotypes
GA3 and GA7 (Fig. 1).
A total of 23 sites had elevated non-synonymous rates (dN)i n
HRSVB, thirteen of which were detected to be under positive
selection by the three methods we used (Table 2). As with
HRSVA, these sites defined lineages within genotypes, again
suggesting that they are not false-positive results. The substitutions
Pro216Ser and Pro219Ser defined the GB4 genotype, while
changes Leu237Pro and Pro219Leu defined genotype GB3, and
Thr255Ala defined SAB3 genotype. Moreover, site 277 changed
from Ser to Phe in genotype JA1 (isolated in Japan) and in the
SAB1 genotype. Finally, positively selected sites 242, 247, 255, 257
and 258 were located immediately upstream of the 20 amino acid-
long duplication region while sites 267, 269 and 270 were located
at the duplication region of the gene. The MPR of positively
selected amino acid changes along the HRSVB tip-dated tree
revealed that sites 222, 227, 255, 257, 276, 291 and 293 were
likewise associated with the split of two distinct branches; (i) one
containing the older samples including prototypes (CH18537 and
Sw860) and non-circulating genotype JA1 and, (ii) other
containing the remaining genotypes (SAB1, SAB2, SAB3 and
GB3) (Fig. 2).
However, perhaps the most notable observation of this analysis
was that 18 of the total of the 55 putatively positively selected sites
in HSRVA and B tended to revert, in time, to a previous codon
state, indicative of a reversible (i.e., ‘‘flip-flop’’) pattern of amino
acid replacement (shown in bold in Table 1 and 2, Fig. 1 and 2).
Eleven of these 18 reversible sites in RSVA and RSVB were found
to be positive selected under the most sensitive model
(MG94xHKY85x3_4x2Rates model) but most by more than one
models and by at least one model. Strikingly, such reversible
evolution occurred at nine sites independently in both HRSVA and
in HRSVB, although two sites in each virus group experienced
reversal without detectable positive selection. For example, site
290 in GA2 genotype reverted from Leu to Pro five times along
the tree (Table 1 and Fig. 1 and 3). Similarly, in some HRSV B
genotypes (GB3 with insertion, GB3 and SAB3) site 219 reverted
from Leu to Pro seven times along the tree (Table 2, Fig. 2 and 4).
Discussion
The Brazilian isolates of G protein sequences of HRSV A and B
demonstrated remarkable genetic flexibility, as noted previously at
the global scale [33,48,49,50,51,52]. Such a high level of genetic
variation may be associated with the fact the G protein plays a key
role in facilitating reinfections in HRSV – allowing evasion from
cross-protective immune responses – and hence in the fluctuating
patterns of viral circulation. As a consequence, describing the
complex patterns of amino acid change in both HRSVA and
HRSVB over time may help understand the evolution and
epidemiology of this important virus.
Our analysis revealed that the ectodomain of the G protein was
subject to strong positive selection, with 29 positively selected
amino acid sites in HRSVA and 23 amino acid sites in HRSVB.
The action of positive selection at these sites was also strongly
supported since 18 of the 52 putatively positive selected sites were
detected using all three forms of dN/dS analysis. Only 5 of the 29
positively-selected sites in HRSVA have described previously (215,
225, 226, 256, 274 and 290) [10,53,54]. Possibly, this difference is
due to the far larger data set available here and/or use of different
analytical methods. Further, many of the positively selected sites in
group A defined genotypes and lineages within genotypes, and
correlated well with known epitopes described in escape-mutants
selected with specific Mabs (sites 226, 237, 265, 274, 275, 284, 286
and 290) [25,49,51] or in natural isolates (sites 215, 225, 226, 265,
280, and 293) [13,25,46]. It is interesting to note that three of these
sites (226, 265, 290) defined genotypes and underwent frequent
reversals (Fig. 1). Site 237 was unique among positively selected
sites in group A in that it had a residue – Asn – with the potential
for N-glycosylation [14]. Moreover, six positively selected sites
(225, 227, 253, 269, 275, 287) were previously described to have
O-linked side chains [1]. The frequency and pattern of
glycosylation were important in defining the antigenicity of the
G protein, either by masking antigenic sites or by recognition of
specific antibodies [55,56]. Less is known about the effects of
amino acid replacements at other sites (222, 227, 230, 243, 246,
248, 249, 272, 279, 285 and 292), although they were located close
together to some of the epitopes involving in neutralizing the virus
(Fig. 3). Moreover, we observed differences in the length of the G
protein due to a stop codon mutation at site 298, and which was
associated with the split of the tree in different branches. In GA5,
Gln298 was maintained but changed to a stop codon (Gln298Stop)
in both GA1 and the lineages leading to all other genotypes GA2,
GA3, GA4, GA6 and GA7. Interestingly, the stop codon at 298
reverted to Trp in the GA2 branch that contains the most recent
isolates. This reflects amino aid replacements involved in the
presentation or elimination of multiple epitopes containing the
three last residues of the G protein (i.e., 296 to 298 C-terminal)
[57].
Although epitopes in HRSVB are not well characterized,
important differences in protein length between Brazilian strains
were observed (295 or 299 amino acids), due to differences in the
occurrence of the final stop codon (site 293). It was suggested that
this region presents an epitope, substitutions in which would
abolish the recognition of the G protein by strain specific
quadrilateral . and the Br I by pink quadrilateral ,. The Fr II is indicated by blue circle . and the Br by blue circle ,. The Fr III is indicated by green
circle . and the Br by green circle ,. The Fr IV is indicated by violet triangle . and the Br by violet triangle,. The Fr V is indicated by orange
quadrilateral . and the Br by orange quadrilateral ,. The Fr VI is indicated by red triangle . and the Br by red triangle ,The Fr VII is indicated by
green triangle . and the Br VII by green triangle ,. The Fr VIII is indicated by gray circle . and the Br VIII by gray circle ,. The Fr IX is indicate by dark
green quadrilateral . and the Br IX by dark green quadrilateral ,.
doi:10.1371/journal.ppat.1000254.g002
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PLoS Pathogens | www.plospathogens.org 6 January 2009 | Volume 5 | Issue 1 | e1000254Table 1. Twenty-nine codon-sites under positive selection in the G gene of HRSVA including nine flip-flop sites (shown in Roman
numerals) that were mapped in viral genealogy shown in Figure 1A, using three methods (Bayes factor .20 and p-value,0.05).
HRSVA
Flip-flops
1 aa position Number of events Change MG94XHKY85 SLAC FEL
215 – Leu Pro * * *
222 – Pro Ser *
I 225 – Val *
FrI Val:Ala 1 Ala *
BrI Ala:Val
II 226 –Pro * * *
Fr II Pro:Leu 1 Leu
Br II Leu:Pro
227 – Thr Ala, Ile, Pro, Ser * *
230–Pro Ser,Leu,Thr * *
237– Asn His, Ser, Asp, Lys, Tyr * *
III 238 – Thr ** *
Fr III Thr:Ile 4 Ile, Ala
Br III Ile:Thr
243 –Ile Thr, Asn * * *
246 –Thr Ile, Met * * *
248 –Leu Phe, His, Val, Phe, Ile, Pro *
249 – Thr Ala, Ile, Asn, Ser * * *
253 –Thr Ala,, Ile *
IV 256 –Pro * * *
Fr IV Pro:Leu 4 Leu
Br IV Leu:Pro
V 265 –Phe *
Fr V Phe:Leu 2 Leu
Br V Leu:Phe
269 –Ser Thr *
VI 272 –Gly Asp, Val, Ser * * *
Fr VI 274 – Leu Pro, Thr *
Br VI Leu:Pro 2
Pro:Leu
275 –Ser Gly, Ile, Asn, Arg * *
VII 279 –V a l * *
Fr VII Val:Ile 1 Ile, Phe
Br VII Ile:Val
280 –Ser Tyr * *
284 –Glu Gly, Lys * * *
285 – Tyr or His Asp, Phe, Asn, Ser * *
VIII 286 – Pro Leu *
Fr VIII Pro:Leu 1
Br VIII Leu:Pro
287 – Ser Leu, Pro * * *
289 –Pro Ser * *
IX 290 –S e r *
Fr IX Pro:Leu 6P r o , L e u
Br IX Leu:Pro
292 – Pro Thr, Ser * *
293 – Pro Ser * *
1Fr- Forward replacements/Br – Backward replacements.
Sites detected by three methods are indicated by *.
doi:10.1371/journal.ppat.1000254.t001
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codon:Gln) divided the tree in two distinct branches, one that
included the ancient non-circulating strains and the other that
included the recent strains. In almost all the Brazilian HRSV GB3
with insertion strains isolated in 2005 we observed an evolutionary
‘‘flip-flop’’ between a glutamine at site 293 and a stop codon,
Table 2. Twenty-three codon-sites under positive selection in the G gene of HRSVB that were mapped in viral genealogy shown in
Figure 1B, using three methods (Bayes factor .20 and p-value,0.05).
HRSVB
Replacements
1 aa position Number of events Changes MG94XHKY85 SLAC FEL
216 – Pro Ser ** *
I 219 –P r o ** *
Fr I Pro:Leu 7 Leu, Ser **
Br I Leu:Pro
222 - Met Thr, Ala **
224 – Lys Arg, Thr **
II 227 – Ile ** *
Fr II Ile:Thr 2T h r **
Br II Thr:Ile
233 – Lys Arg, Glu *
III 235 –P r o ** *
Fr III Pro:Leu 1 Leu
Br III Leu:Pro
IV 237 – Leu Pro ** *
Fr IV Pro:Ser 3 Pro:Ser ** *
Br IV Ser:Pro
242 –Arg Gly *
246- Thr Ile *
247 – Ser Pro ** *
V 255 –Ile Thr ** *
Fr V Thr:Ala 1 Thr:Ala
Br V Ala:Thr
VI 257 –P r o ** *
Fr VI Pro:Ser 1 Ser
Br VI Ser:Pro
258 – Lys Asp, Asn, Gly **
269
" – Ser Leu, Pro, Phe ** *
VII 270
" – Thr Ile **
Fr VII Thr:Ile 2
Br VII Ile:Thr
285(265) – Ser Phe, Pro, Thr, Tyr ** *
VIII 286 (266) – Leu **
Fr VIII Leu:Pro 1P r o
Br VIII Pro:Leu
297 (277) – Ser Phe ** *
305 (285) –Glu Asp, Lys *
306 (286) –Pro Leu *
311 (291) –Pro Ser ** *
IX 313 (293) – Stop **
Fr IX Stop: Gln 5G l n
Br IX Gln :Stop
"Sites inside the 60 nt insertion. Positions between parentheses are position in sequences that do not have the 60 nt insertion. Sites 233, 246 and 275 were detected as
being under elevated dN/dS, but show only apical changes in the tree and were excluded.
1Fr- Forward replacements/Br – Backward replacements.
Sites detected by three methods are indicated by *.
doi:10.1371/journal.ppat.1000254.t002
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Remarkably, other sites experienced similar reversals, such as
amino acids 219, 227, 237 and 257, which defined new genotypes,
suggesting that there are a limited number of amino acid residues
at this site that allow successful virus attachment glycoprotein.
Indeed, HRSV escape mutants that differ in their last 81 residues
from the canonical Long prototype protein sequence, retain their
compositions and hydropathy profiles [25], strongly suggesting
that there may be indeed structural restrictions to changes in the G
protein, although this will need to be investigated further. Finally,
positively selected sites located in the 20 amino acid duplicated
region of the gene, and immediately upstream of it may influence
the expression of some important epitopes. For example, the
additional O-linked glycosylation residues in both the insertion
and duplication regions probably confers advantage of this new
variant over the other HRSVB genotypes. Of the 23 positively
Figure 3. Graphical representation of the third C-terminal hypervariable region of HRSVA G [Long strain], showing a partial
antigenic map. The amino acid changes associated with epitope loss in natural isolates and in escape mutants selected with specific Mabs are
indicated by arrows [4,15,24,40]. The positions, relative to the Long strain, of codons with evidence of positive selection that also experienced
evolutionary reversals are shown by Roman numbers and coloured arrows.
doi:10.1371/journal.ppat.1000254.g003
Figure 4. Graphical representation of the third C-terminal hypervariable region of HRSVB G (CH18537). The positions of the first amino
acid in the amplicon and that for the insertion are shown in relation to the CH18537 isolate. The codon positions of sites with evidence of positive
selective pressure that also experienced evolutionary reversals are indicated by Roman numbers and by coloured arrows.
doi:10.1371/journal.ppat.1000254.g004
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Zlateva et al. 2005 (sites 219, 237, 247, 257 and 258) and, two by
Woelk and Holmes, 2001 (sites 227 and 257). Consequently,
HRSV appears to be subject to far greater positive selection
pressure than previously realized.
Our data also identified amino acid sites under positive selection
sharing positional homology in the two groups. For example, 11
positively selected sites in HRSVA (215, 226, 246, 256, 265, 274,
275, 284, 285, 290 and 292) had positional homologues in
HRSVB (216, 227, 247, 257, 266, 275, 276, 285, 286, 291 and
293). Some of these sites are known to harbor epitopes in HRSVA
(215, 226, 265, 275, 284 and 290). Moreover, some sites were
important in defining lineages in the phylogenetic tree, such as
sites 215, 265, 274, 286 and 290, specific to prototypes and non-
circulating GA1 genotypes and site 226 defining the GA2
genotype. Less is known about epitopes in HRSVB, but sites
227, 257, 276, 291 and 293, under positive selection, were
associated with the major division of the HRSVB phylogenetic
tree into two branches.
The most interesting observation from this analysis was that
both HRSVA and HRSVB experienced frequent evolutionary
reversals of amino acids at positively-selected sites Tables 1 and 2,
Figs. 1 and 2), which in turn mapped to known and possibly newly-
described epitopes (Figs. 3 and 4). That most of the sites
experiencing this ‘‘flip-flop’’ evolutionary pattern were also under
positive selection strongly suggests that they reflect the fluctuating
dynamics in the immune status of human populations, in which
patterns of cross-protective immunity ebb and wane. To be more
specific, the build-up of lineage-specific resistance in the host
population would drive the process of positive selection in key
immunological epitopes. Later, following the loss of herd
immunity to the previous viral epitope, coupled with constraints
which mean that only a limited number of amino acids are
functionally viable, a reversion mutation would be fixed by positive
selection in a newly susceptible human population. In sum, the
frequent evolutionary reversals observed in the G protein of
HRSV are a necessary consequence of a limited set of possible
replacements at HRSV epitopes. Without such a constraint on the
repertoire of functionally viable amino acids we would expect to
see a gradual diversification at these sites rather than frequent
reversals. This model agrees well with the spacing of temporal
events observed in both viral phylogenies, supporting the notion
that reversible evolution may contribute to the escape from the
human population immune response, thereby facilitating viral
transmission. A clearer understanding of the determinants of the
evolutionary reversals within the G protein could ultimately lead
to a better understanding of the viral immune-escape repertoire
and assist in the control of HRSV.
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